Indolizine compounds, a process for their preparation and pharmaceutical compositions containing them

Patent metadata

Field	Value
Publication number	US-10414754-B2
Application number	US-201815906389-A
Country	US
Kind code	B2
Filing date	Feb 27, 2018
Priority date	Jul 23, 2013
Publication date	Sep 17, 2019
Grant date	Sep 17, 2019

Abstract

Compounds of formula (I) wherein Ra, Rb, Rc, Rd, T, R3, R4, R5, X, Y and Het are as defined in the description.

Medicinal products containing the same which are useful in treating pathologies involving a deficit in apoptosis, such as cancer, auto-immune diseases, and diseases of the immune system.

First claim

The invention claimed is:

1. A method of treating cancer in a subject in need thereof, wherein the cancer is selected from cancers of the bladder, brain, breast and uterus, chronic lymphoid leukaemias, colorectal cancer, cancers of the œsophagus and liver, lymphoblastic leukaemias, non-Hodgkin lymphomas, melanomas, malignant haemopathies, myelomas, ovarian cancer, non-small-cell lung cancer, prostate cancer and small-cell lung cancer, comprising administration of a compound of formula (I):

wherein:
X and Y represent a carbon atom or a nitrogen atom, it being understood that they may not simultaneously represent two carbons atoms or two nitrogen atoms;
the Het moiety of the group

 represents an optionally substituted, aromatic or non-aromatic ring composed of 5, 6 or 7 ring members, which may have, in addition to the nitrogen represented by X or by Y, from one to 3 hetero atoms selected independently from oxygen, sulphur and nitrogen, it being understood that the nitrogen in question may be substituted by a group representing a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group or a —C(O)—O-Alk group wherein Alk is a linear or branched (C 1 -C 6 )alkyl group;
T represents a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group optionally substituted by from one to three halogen atoms, a (C 2 -C 4 )alkyl-NR 1 R 2 group, or a (C 1 -C 4 )alkyl-OR 6 group;
R 1 and R 2 independently of one another represent a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group,
or R 1 and R 2 , together with the nitrogen atom carrying them, form a heterocycloalkyl;
R 3 represents a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, a cycloalkyl group, a (C 3 -C 10 )cycloalkyl-(C 1 -C 6 )alkyl group wherein the alkyl moiety is linear or branched, a heterocycloalkyl group, an aryl group or a heteroaryl group, it being understood that one or more of the carbon atoms of the preceding groups, or of their possible substituents, may be deuterated;
R 4 represents an aryl group, a heteroaryl group, a cycloalkyl group or a linear or branched (C 1 -C 6 )alkyl group, it being understood that one or more of the carbon atoms of the preceding groups, or of their possible substituents, may be deuterated;
R 5 represents a hydrogen or halogen atom, a linear or branched (C 1 -C 6 )alkyl group, or a linear or branched (C 1 -C 6 )alkoxy group;
R 6 represents a hydrogen atom or a linear or branched (C 1 -C 6 )alkyl group;
R a , R b , R c and R d , each independently of the others, represent a hydrogen atom, a linear or branched (C 1 -C 6 )alkyl group, a linear or branched (C 2 -C 6 )alkenyl group, a linear or branched (C 2 -C 6 )alkynyl group, an aryl group or a heteroaryl group, a halogen atom, a linear or branched (C 1 -C 6 )alkoxy group, a hydroxy group, a linear or branched (C 1 -C 6 )polyhaloalkyl group, a trifluoromethoxy group, —NR 7 R 7 ′, nitro, R 7 —CO—(C 0 -C 6 )alkyl-, R 7 —CO—NH—(C 0 -C 6 )alkyl-, NR 7 R 7 ′—CO—(C 0 -C 6 )alkyl-, NR 7 R 7 ′—CO—(C 0 -C 6 )alkyl-O—, R 7 —SO 2 —NH—(C 0 -C 6 )alkyl-, R 7 —NH—CO—NH—(C 0 -C 6 )alkyl-, R 7 —O—CO—NH—(C 0 -C 6 )alkyl-, a heterocycloalkyl group, or the substituents of one of the pairs (R a ,R b ), (R b ,R c ) or (R c ,R d ), together with the carbon atoms carrying them, form a ring composed of from 5 to 7 ring members, which may have from one to 2 hetero atoms selected from oxygen and sulphur, it being understood that one or more carbon atoms of the ring defined hereinbefore may be deuterated or substituted by from one to 3 groups selected from halogen and linear or branched (C 1 -C 6 )alkyl;
R 7 and R 7 ′, each independently of the other, represent a hydrogen, a linear or branched (C 1 -C 6 )alkyl, a linear or branched (C 2 -C 6 )alkenyl, a linear or branched (C 2 -C 6 )alkynyl, an aryl or a heteroaryl, or R 7 and R 7 ′, together with the nitrogen atom carrying them, form a heterocycle composed of from 5 to 7 ring members;

wherein the aryl, heteroaryl, cycloalkyl and heterocycloalkyl groups so defined and the groups alkyl, alkenyl, alkynyl and alkoxy may be optionally substituted by from 1 to 3 groups selected from optionally substituted, linear or branched (C 1 -C 6 )alkyl, (C 3 -C 6 )spiro, optionally substituted, linear or branched (C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl-S—, hydroxy, oxo (or N-oxide where appropriate), nitro, cyano, —COOR′, —OCOR′, NR′R″, linear or branched (C 1 -C 6 )polyhaloalkyl, trifluoromethoxy, (C 1 -C 6 )alkylsulphonyl, halogen, optionally substituted aryl, heteroaryl, aryloxy, arylthio, cycloalkyl, heterocycloalkyl optionally substituted by one or more halogen atoms or alkyl groups, it being understood that R′ and R″, each independently of the other, represent a hydrogen atom or an optionally substituted, linear or branched (C 1 -C 6 )alkyl group,

and wherein the Het moiety of the group defined in formula (I) may be optionally substituted by from one to three groups selected from linear or branched (C 1 -C 6 )alkyl, hydroxy, linear or branched (C 1 -C 6 )alkoxy, NR 1 ′R 1 ″ and halogen, wherein R 1 ′ and R 1 ″, each independently of the other, represent a hydrogen atom or an optionally substituted, linear or branched (C 1 -C 6 )alkyl group,
it being understood that:
“aryl” means a phenyl, naphthyl, biphenyl or indenyl group,
“heteroaryl” means any mono- or bi-cyclic group composed of from 5 to 10 ring members, having at least one aromatic moiety and containing from 1 to 4 hetero atoms selected from oxygen, sulphur and nitrogen (including quaternary nitrogens),
“cycloalkyl” means any mono- or bi-cyclic, non-aromatic, carbocyclic group containing from 3 to 10 ring members,
“heterocycloalkyl” means any mono- or bi-cyclic, non-aromatic, condensed or spiro group containing from 3 to 10 ring members and containing from 1 to 3 hetero atoms selected from oxygen, sulphur, SO, SO 2 and nitrogen,

its enantiomers and diastereoisomers, and addition salts thereof with a pharmaceutically acceptable acid or base, wherein the compound of formula (I) is administered alone or in combination with one or more pharmaceutically acceptable excipients.

2. The method according to claim 1 , wherein the group

represents: 5,6,7,8-tetrahydroindolizine optionally substituted by an amino group; indolizine; 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine optionally substituted by a methyl; or pyrrolo[1,2-a]pyrimidine.

3. The method according to claim 1 , wherein T represents hydrogen, methyl, 2-(morpholin-4-yl)ethyl, 3-(morpholin-4-yl)propyl, —CH 2 —OH, 2-aminoethyl, 2-(3,3-difluoropiperidin-1-yl)ethyl, 2-[(2,2-difluoroethyl)amino]ethyl or 2-(3-methoxyazetidin-1-yl)ethyl.

4. The method according to claim 1 , wherein R a and R d each represent a hydrogen atom and (R b ,R c ), together with the carbon atoms carrying them, form a 1,3-dioxolane group or a 1,4-dioxane group; or R a , R c and R d each represent a hydrogen atom and R b represents a hydrogen, a halogen, a methyl or a methoxy; or R a , R b and R d each represent a hydrogen atom and R c represents a hydroxy or methoxy group.

5. The method according to claim 1 , wherein R 4 represents a 4-hydroxyphenyl group.

6. The method according to

Assignees

• Servier Lab
• Vernalis R&D Ltd

Inventors

• Le Tiran Arnaud
• Le Diguarher Thierry
• Starck Jérôme-Benoît
• Henlin Jean-Michel
• De Nanteuil Guillaume
• Geneste Olivier
• Davidson James Edward Paul
• Murray James Brooke
• Chen I-Jen

Classifications

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P35/02

  specific for leukemia · CPC title